Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally

Summary

Biopharmaceutical stocks require time and patience. But when the company gets it right, investors get rewarded as they have with Kiniksa Pharmaceuticals NASDAQ: KNSA. The stock is up over 100% in the last year. Much of that growth came after the company’s strong Q1 earnings report on April 28, in which it topped adjusted earnings per share (EPS) estimates by 9 cents, coming in at 27 cents. Kiniksa Pharmaceuticals International TodayKNSAKiniksa Pharmaceuticals International$53.24 -0.41 (-0.76%) As of 05/22/2026 04:00 PM Eastern52-Week Range$25.70▼$59.87P/E Ratio59.16Price Target$60.86 At that time, the company announced the launch of a targeted direct-to-consumer TV campaign for ARCALYST in recurrent pericarditis. ARCALYST is the first and only U.S. Food & Drug Administration (FDA) approved therapy for recurrent pericarditis. It received this designation in 2021. After some initial volatility, ARCALYST saw revenue of about $48 million in March 2023. Revenue growth has accelerated, reaching a new record of $214.27 million in Q1 2026, a 56% year-over-year (YOY) gain. The new campaign is significant because it shows that Kiniksa is investing in demand generation at scale rather than relying solely on prescriber growth. To that end, the company raised its full-year revenue guidance to $930 million to $945 million. The prior guidance was for a range between $900 million and $920 million. A Singular Focus Moving Into Its Second GenerationLike many biotech companies, Kiniska focuses on discovering and advancing novel, transformative therapies for patients with unmet medical needs. The company’s specific focus is on cardiovascular diseases, specifically pericarditis. Pericarditis is an inflammation of the pericardium—the thin, fluid-filled sac surrounding the heart—that causes sharp chest pain, fatigue, and in severe cases, dangerous fluid buildup around the heart. When the condition keeps coming back despite standard anti-inflammatory treatments like NSAIDs and colchicine, ...